Lung cancer has become the leading cause of death from cancer throughout the western world. Its 5-year survival rate is among the worst for prevalent cancers, remaining at 5% to 15% in recent years.
Expertise among 20 contributors addresses the clinical background on incidence, etiology, pathology, molecular biology, diagnosis, treatment, and staging. Merits of surgery, chemotherapy, and radiation alone and in combination are considered in depth and documented from published clinical trials. Newer therapy with single agents such as the topoisomerase inhibitors, taxanes, and gemcitabine as well as combinations are discussed. Recognizing that even the most promising of these regimens are far from ideal, new treatments based on immunologic concepts have acquired a role in treatment and include biologic agents targeting growth factor receptors. A recent editorial in the New England Journal of Medicine (Carney DN. 2002; 346:127) discusses the limitations of current therapy and outlines some innovative approaches including chemoprevention and growth factor receptor blockade that may prove more effective than current therapy. The coagulationist needs to know about lung cancer because of the testing frequently ordered by oncologists.
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